Increased AUC
0-inf w/ gemfibrozil, itraconazole. Decreased AUC
0-inf w/ rifampin. Decreased AUC of midazolam, S-warfarin, omeprazole & docetaxel. Concomitant use w/ analgesics (eg, fentanyl, tramadol), antibiotics (eg, clarithromycin, doxycycline), anticancer agents (eg, cabazitaxel), antiepileptics (eg, carbamazepine, clonazepam, phenytoin, primidone, valproic acid), antipsychotics (eg, haloperidol), antithrombotics (eg, acenocoumarol, warfarin, clopidogrel), β-blockers (eg, bisoprolol, propranolol), Ca channel blockers (eg, diltiazem, felodipine, nicardipine, nifedipine, verapamil), cardiac glycosides (eg, digoxin), corticosteroids (eg, dexamethasone, prednisolone), HIV antivirals (eg, indinavir, ritonavir), hypnotics (eg, diazepam, midazolam, zolpidem), immunosuppressives (eg, tacrolimus), PPIs (eg, omeprazole), statins metabolized by CYP3A4 (eg, atorvastatin, simvastatin), thyroid agents (eg, levothyroxine); medicinal products w/ narrow therapeutic range that are P-gp substrates (eg, colchicine, dabigatran etexilate, digoxin). Increased AUC & Cmax of digoxin. Possible loss of pharmacological effects of CYP2B6, CYP3A4, CYP2C9, CYP2C19 or UGT1A1 substrates. Possible induction of MRP2, organic anion transporter 3 & organic cation transporter 1.